Core Viewpoint - Huason Pharmaceutical (002907.SZ) reported its Q3 2025 results, highlighting a significant presence of institutional investors holding 41.91% of its total shares, although this represents a decline from the previous quarter [1] Institutional Holdings - As of October 28, 2025, seven institutional investors disclosed holdings in Huason Pharmaceutical, totaling 175 million shares [1] - The institutional investors include Chengdu Local Construction Machinery Engineering Co., Shanghai Tiancheng Investment Management Co., Hong Kong Central Clearing Limited, and several asset management products from Dajia Asset Management and Dajia Life Insurance [1] - The total institutional holding percentage decreased by 1.59 percentage points compared to the previous quarter [1] Public Fund Activity - In this reporting period, 18 public funds were not disclosed compared to the previous quarter, including notable funds such as Bosera Chengyu Economic Circle ETF and Huatai-PB CSI 2000 Index Enhanced A [1] Foreign Investment Trends - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.34% compared to the previous quarter [1] - Barclays Bank PLC was noted as a foreign institution that did not disclose holdings in this period [1]

Core Viewpoint - The company has reported a significant decline in net profit and cash flow due to increased R&D expenses and tax payments, while also announcing a change in its drug production license to expand its production range [5][10]. Financial Performance - The net profit attributable to shareholders decreased by 32.37% year-on-year, while the net profit excluding non-recurring gains and losses fell by 70.50% [5]. - The net cash flow from operating activities dropped by 76.80% compared to the same period last year, primarily due to increased purchases and tax payments [5]. Non-Recurring Gains and Losses - The company reported a non-recurring gain of 51,027.96 yuan from personal income tax refunds and an investment income of 9,523,206.11 yuan from a merger [3][5]. License Change - The company received a new drug production license that expands its production range to include the raw material drug, Benzosulfone Melogabalin, which is intended for the production of Benzosulfone Melogabalin tablets [8][9]. - This change is expected to enhance the integration of raw material and formulation production, aiding in cost control and efficiency [10].

（文章来源：证券日报） 证券日报网讯 10月28日晚间，华森制药发布公告称，公司于近日收到重庆市药品监督管理局颁发的 《药品生产许可证》，本次变更主要涉及增加生产范围（仅限药品注册申报）。 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-081 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监督 管理局颁发的《药品生产许可证》（许可证编号：渝 20150018），本次变更主要 涉及增加生产范围（仅限药品注册申报）。具体情况如下： 一、变更内容 1.增加生产范围（仅限药品注册申报）：原料药（苯磺酸美洛加巴林）。 二、变更后的《药品生产许可证》具体内容 | 企 | 业 | | 名 | 称：重庆华森制药股份有限公司 | | --- | --- | --- | --- | --- | | 许 | 可 | 证 | 编 | 号：渝 20150018 | | 社 | 会 | 信 用 | 代 | 码：915002262038944463 | | 分 | | 类 | | 码：AhzyBhzChDh | | 注 | 册 | | 地 | 址：重庆市荣昌区工业园区 | | 法 | 定 | 代 | 表 | 人：游洪涛 | | 企 | 业 | 负 | 责 | 人：游洪涛 | | 质 | 量 | 负 | 责 | 人：邓林 | | 质 | 量 | 受 | 权 | 人：王茜 | | 生 | 产 ...

重庆华森制药股份有限公司 2025 年第三季度报告 证券代码：002907 证券简称：华森制药 公告编号：2025-080 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 重庆华森制药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 重庆华森制药股份有限公司 2025 年第三季度报告 （二） 非经常性损益项目和金额 适用 □不适用 | | | 单位：元 | | | --- | --- | --- | --- | | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | 非流动性资产处置损益（包 | 8,424,826.37 | 8,325,037.25 | | | 括已计提资产减值准备的冲 | | | ...

Core Viewpoint - Huason Pharmaceutical (002907) announced that its crizotinib capsules are currently under patent protection by the original research company and are expected to be available for sale by the end of next year [1] Company Summary - The sales of the drug are influenced by various industry policies, and the company is currently unable to estimate the sales revenue [1]

Core Viewpoint - Huason Pharmaceutical has received the drug registration certificate for its product Crizotinib capsules from the National Medical Products Administration [1] Group 1 - The announcement was made on the evening of October 20 [1] - The approval signifies a regulatory milestone for Huason Pharmaceutical in bringing Crizotinib to market [1]

Core Viewpoint - Huason Pharmaceutical has received the drug registration certificate for Crizotinib capsules from the National Medical Products Administration, marking a significant milestone in its oncology product portfolio [1] Group 1: Company Developments - The approval of Crizotinib capsules allows Huason Pharmaceutical to treat ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, as well as ROS1-positive advanced NSCLC patients [1] - Huason Pharmaceutical becomes the second company in the country to obtain approval for this product, filling a gap in its oncology offerings [1] - The introduction of this drug is expected to enhance the company's brand influence in the oncology segment [1]

Core Viewpoint - The company received approval from the National Medical Products Administration for its product, Crizotinib capsules, which has been in the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Company Summary - Crizotinib capsules are primarily used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) and for patients with advanced NSCLC who are positive for ROS1 [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-079 重庆华森制药股份有限公司 关于公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于公司产品克唑替尼胶囊（以 下简称"该药品"）的《药品注册证书》（证书编号：2025S03143），现将相关 情况公告如下： 一、药品的基本情况 | 药 | | 品 | 名 | | 称：克唑替尼胶囊 | | --- | --- | --- | --- | --- | --- | | 英 | 文 | 名 | 拉 / | 丁 | 名：Crizotinib Capsules | | 受 | | | 理 | | 号：CYHS2401414 | | 证 | | 书 | 编 | | 号：2025S03143 | | 剂 | | | | | 型：胶囊剂 | | 规 | | | | | 格：0.25g | | 注 | | 册 | 分 | | 类：化学药品 4 类 | | 处 | 方 | 药 ...